Literature DB >> 26864507

Transient Hypothyroidism after Radioiodine for Graves' Disease: Challenges in Interpreting Thyroid Function Tests.

Michael T Sheehan1, Suhail A R Doi2.   

Abstract

Graves' disease is the most common cause of hyperthyroidism and is often managed with radioactive iodine (RAI) therapy. With current dosing schemes, the vast majority of patients develop permanent post-RAI hypothyroidism and are placed on life-long levothyroxine therapy. This hypothyroidism typically occurs within the first 3 to 6 months after RAI therapy is administered. Indeed, patients are typically told to expect life-long thyroid hormone replacement therapy to be required within this timeframe and many providers expect this post-RAI hypothyroidism to be complete and permanent. There is, however, a small subset of patients in whom a transient post-RAI hypothyroidism develops which, initially, presents exactly as the typical permanent hypothyroidism. In some cases the transient hypothyroidism leads to a period of euthyroidism of variable duration eventually progressing to permanent hypothyroidism. In others, persistent hyperthyroidism requires a second dose of RAI. Failure to appreciate and recognize the possibility of transient post-RAI hypothyroidism can delay optimal and appropriate treatment of the patient. We herein describe five cases of transient post-RAI hypothyroidism which highlight this unusual sequence of events. Increased awareness of this possible outcome after RAI for Graves' disease will help in the timely management of patients.
© 2016 Marshfield Clinic.

Entities:  

Keywords:  Graves disease; Hypothyroidism; Radioiodine therapy; Thyroid hormones; Treatment outcome

Mesh:

Substances:

Year:  2016        PMID: 26864507      PMCID: PMC4851449          DOI: 10.3121/cmr.2015.1297

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  18 in total

Review 1.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.

Authors:  Y Aizawa; K Yoshida; N Kaise; H Fukazawa; Y Kiso; N Sayama; H Hori; K Abe
Journal:  Clin Endocrinol (Oxf)       Date:  1997-01       Impact factor: 3.478

3.  Thyroid stunning in vivo and in vitro.

Authors:  Mario Medvedec
Journal:  Nucl Med Commun       Date:  2005-08       Impact factor: 1.690

4.  Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.

Authors:  A Allahabadia; J Daykin; M C Sheppard; S C Gough; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

5.  Age and gender predict the outcome of treatment for Graves' hyperthyroidism.

Authors:  A Allahabadia; J Daykin; R L Holder; M C Sheppard; S C Gough; J A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

6.  The epidemiology of thyroid disease.

Authors:  Mark P J Vanderpump
Journal:  Br Med Bull       Date:  2011       Impact factor: 4.291

7.  Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with Graves' disease.

Authors:  G-M Shi; Q Xu; C-Y Zhu; Y-L Yang
Journal:  J Int Med Res       Date:  2009 Mar-Apr       Impact factor: 1.671

8.  Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves' disease.

Authors:  D B Turton; E D Silverman; K M Shakir
Journal:  Clin Nucl Med       Date:  1998-12       Impact factor: 7.794

9.  Transient hypothyroidism after iodine-131 therapy for Grave's disease.

Authors:  N Gómez; J M Gómez; A Orti; L Gavaldà; C Villabona; P Leyes; J Soler
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

10.  Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease.

Authors:  H L Uy; C A Reasner; M H Samuels
Journal:  Am J Med       Date:  1995-08       Impact factor: 4.965

View more
  5 in total

Review 1.  Recurrent Graves' hyperthyroidism after prolonged radioiodine-induced hypothyroidism.

Authors:  Fariha Salman; Hooman Oktaei; Solomon Solomon; Ebenezer Nyenwe
Journal:  Ther Adv Endocrinol Metab       Date:  2017-09-12       Impact factor: 3.565

2.  Thermal ablation of thyroid nodules: are radiofrequency ablation, microwave ablation and high intensity focused ultrasound equally safe and effective methods?

Authors:  Yücel Korkusuz; Daniel Gröner; Natascha Raczynski; Oleg Relin; Yasmina Kingeter; Frank Grünwald; Christian Happel
Journal:  Eur Radiol       Date:  2017-09-11       Impact factor: 5.315

3.  Finding the best effective way of treatment for rapid I-131 turnover Graves' disease patients: A randomized clinical trial.

Authors:  Siwaporn Thamcharoenvipas; Stephen J Kerr; Supatporn Tepmongkol
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Incidences of Hypothyroidism Associated With Surgical Procedures for Thyroid Disorders: A Nationwide Population-Based Study.

Authors:  Shin-Han Tsai; Shuo-Chen Chien; Phung-Anh Nguyen; Po-Han Chien; Hon-Ping Ma; Rahma Novita Asdary; Yao-Chin Wang; Ayesha Humayun; Chen-Ling Huang; Usman Iqbal; Wen-Shan Jian
Journal:  Front Pharmacol       Date:  2019-12-12       Impact factor: 5.810

5.  Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men.

Authors:  Yetunde Ajoke Onimode; David Magbagbeola Dairo; Annare Ellmann
Journal:  Pan Afr Med J       Date:  2018-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.